Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyell Immunopharma (LYEL) Asset Writedowns and Impairment: 2021-2024

  • Lyell Immunopharma's Asset Writedowns and Impairment was N/A to $51.3 million in Q4 2024 from the same period last year, while for Dec 2024 it was $87.7 million, marking a year-over-year change of. This contributed to the annual value of $51.3 million for FY2024, which is N/A change from last year.
  • Latest data reveals that Lyell Immunopharma reported Asset Writedowns and Impairment of $51.3 million as of Q4 2024, which was up 1,126.00% from -$5.0 million recorded in Q4 2022.
  • Over the past 5 years, Lyell Immunopharma's Asset Writedowns and Impairment peaked at $51.3 million during Q4 2024, and registered a low of -$5.0 million during Q4 2022.
  • For the 2-year period, Lyell Immunopharma's Asset Writedowns and Impairment averaged around $17.1 million, with its median value being $5.0 million (2022).
  • Data for Lyell Immunopharma's Asset Writedowns and Impairment shows a maximum YoY slumped of 113.72% (in 2022) over the last 5 years.
  • Lyell Immunopharma's Asset Writedowns and Impairment (Quarterly) stood at $36.4 million in 2021, then tumbled by 113.72% to -$5.0 million in 2022, then reached $51.3 million in 2024.
  • Its Asset Writedowns and Impairment was $51.3 million in Q4 2024, compared to -$5.0 million in Q4 2022 and $5.0 million in Q3 2022.